Wedbush analyst Laura Chico maintained a Buy rating on Viridian Therapeutics today and set a price target of $42.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laura Chico’s rating is based on several strategic developments and financial maneuvers by Viridian Therapeutics that position the company for future growth. The completion of a $251 million secondary offering and a new credit facility have strengthened the company’s financial standing, allowing for increased R&D and SG&A expenditures. Additionally, the recent royalty financing agreement with DRI Healthcare provides up to $300 million in potential funds, further bolstering the company’s financial resources.
2026 is anticipated to be a pivotal year for Viridian Therapeutics, with significant milestones expected. The imminent filing of the veligrotug BLA and the upcoming Phase 3 study readouts for VRDN-003 are key events that could enhance the company’s market position. If these developments proceed positively, Viridian could become a leading player in the TED space, particularly with the potential commercial launch of veligrotug in the latter half of 2026. These factors collectively contribute to Laura Chico’s Buy rating for Viridian Therapeutics.
In another report released on October 21, H.C. Wainwright also reiterated a Buy rating on the stock with a $34.00 price target.